Study in Patients With Asthma

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine which dose of the investigational drug is safest and most effective compared to the control group.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dey
• Treatments: Formoterol Fumarate

Criteria

Inclusion Criteria:

• Require the regular use of an inhaled beta-2-selective adrenergic agent.

• No clinically significant abnormalities on the medical history, physical examination, and clinical laboratory tests.

Exclusion Criteria:

• Active acute or chronic disorders of the respiratory system within one month prior to screening.

• Smoking history within the past 12 months or greater than a lifetime 10 pack-year smoking history.

• Debilitating systemic and/or life-threatening diseases.